Introduction
============

Background of drug-eluting stent development
--------------------------------------------

After the advent of cardiac catheterization in the late 1920s and the development of coronary angiographic technology in the late 1950s, balloon angioplasty (BA) was introduced in the mid 1960s. Balloon angioplasty was first applied to the revascularization of the femoral, popliteal, and renal arteries, and was adapted to the coronary arteries in the late 1970s ([@b18]; [@b16]; [@b31], [@b32]). There were important limitations of coronary BA, including the risk of uncontrollable plaque disruption and vascular recoil that may lead to periprocedural coronary occlusion and myocardial infarction, and a 20%--40% incidence of restenosis within 6--12 months after successful revascularization, which compromises the longterm prognosis ([@b49]). Various atherectomy techniques such as rotational atherectomy (rotablation), Excimer Laser Coronary Angioplasty (ELCA), and Directional Coronary Atherectomy (DCA) were developed in late 1980s and early 1990s, but these devices did not significantly improve the long-term outcome due to a lack of an impact on restenosis rate ([@b56]; [@b34]). On the other hand, scaffolding metallic mesh, called stent, was developed during the same period to prevent restenosis after BA. The clinical efficacy of stent compared with conventional BA was studied in two landmark clinical trials. The North American [St]{.ul}ent [Res]{.ul}tenosis [S]{.ul}tudy (STRESS) showed a lower angiographic restenosis rate (31.6% vs 42.1%) and a lower target vessel revascularization (TVR) rate (10.2% vs 15.4%) in stent group than in BA group ([@b17]). The European comparison of balloon-expandable-stent implantation with BA in patients with coronary artery disease by the Benestent Study Group proved a similar, but more impressive, reduction of restenotic rate (22% vs 32%) (p = 0.02) and TVR rate (13.1% vs 22.9%) (p = 0.005) in stent group compared with BA group ([@b73]). Based on the result of these two studies, Palmaz-Schatz balloon-expandable stent (Cordis Corp; a Johnson and Johnson Company, Warren, NJ, USA) was approved as the first bare metal stent (BMS) for elective use by Food and Drug Administration (FDA) in 1994 after Gianturco-Roubin coil stent (Cook Inc, Bloomington, IN, USA) was approved as the first BMS for acute closure in 1993 ([@b56]). However, the sudden occlusion of vessel due to subacute stent thrombosis (SAT) and late in-stent restenosis (ISR) are two major complications that were initially encountered with the widespread use of BMS. Although the SAT rate has been reduced to approximately 1% with adequate antiplatelet therapy (ie, aspirin and clopidogrel), the incidence of ISR is still a hindrance to the long-term success of the stenting procedure ([@b68], [@b69]). When the use of BMS was expanded in the high-risk restenosis groups of patients such as those with small vessel, long and bifurcation lesions, and diabetes mellitus, ISR and TVR escalated to the range of 50%--60% and 30%--50%, respectively ([@b92]). Extensive research was carried out in the late 1990s to seek a solution to the problem of ISR. Brachytherapy with insertion of radioactive devices in the coronary artery was initially developed to prevent ISR ([@b60]). Despite its moderate success, brachytherapy had limitations such as late thrombosis, geographic mismatch, relatively high cost, and requirement of radiation oncologists, which made it unsuitable for widespread and routine clinical practice ([@b60]). During the period when the brachytherapy was becoming the treatment of choice of in-stent restenosis, clinical trials of drug-eluting stents (DES) demonstrated a pristine outcome with a very high success rate and very low in-stent restenosis rate. DES has now become the mainstream therapy of coronary artery stenosis due to the expected very low rate of in-stent restenosis and brachytherapy has become a thing of the past.

Pathophysiology of ISR and mechanism of action of DES to prevent ISR
--------------------------------------------------------------------

Three distinct processes are involved in the pathogenesis of ISR as depicted in [Figure 1](#fig1){ref-type="fig"}. These include: (1) immediate vessel recoil after stretch injury, (2) negative arterial remodeling, and (3) neointimal hyperplasia ([@b28]; [@b50]; [@b41]; [@b57]). Elastic recoil is the immediate shrinkage of vessel after percutaneous coronary intervention (PCI) due to the elastic properties of arterial wall, which usually occurs within 24 hours after procedure. Negative remodeling is a process of local contraction of arterial wall and narrowing of the lumen at the injured vascular segment. It may be related to the healing process as well as the interaction between endothelial cells and nonlaminar blood flow ([@b42]). Neointimal hyperplasia is the proliferation and migration of smooth muscle cells from the media, possibly circulating cells from bone marrow into the intima, and then encroach on the vascular lumen ([@b42]). Negative remodeling and neointimal proliferation usually occur weeks to months after PCI ([@b42]). The first two pathological processes were the main causes of restenosis in BA, but were basically eliminated by use of stent. The third mechanism, neointimal hyperplasia, becomes the only major mechanism in the pathogenesis of ISR ([@b87]).

![Pathophysiology of in-stent restenosis and the mechanisms of action of different therapeutic agents.\
**Abbreviations:** ECM, extracellular matrix; SMC, smooth muscle cells.](vhrm0104-263-f1){#fig1}

Mechanism of neointimal hyperplasia
-----------------------------------

Immediately after stenting, the denuded endothelial surface and disrupted medial tissue of arterial wall due to mechanical trauma triggered an inflammatory process, which led to platelet adhesion, activation, and aggregation, and subsequently fibrin deposition and thrombus formation within the stent (thrombotic phase: day 0--3) ([@b42]). These microthrombi as well as the stretch injury of the vessel wall attract inflammatory cells such as macrophages and lymphocytes, which demarginate from the bloodstream and also from vasa vasorum (recruitment phase: day 3--8). These inflammatory cells stimulate the production of various growth factors and cytokines locally, which activate the dormant (G~0~ phase) vascular smooth muscle cells in the media and also possibly recruit the circulating stem cells to re-enter into cell cycle and replicate. These proliferating smooth muscle cells subsequently migrate into the intima and thrombus in the stent lumen and eventually form a neointimal layer within the stent lumen (proliferative phase: day 8, healing) ([@b70]). Even though cell proliferation ceases at 2 weeks after the initial injury, these smooth muscle cells continue to produce abundant extracellular matrix, which leads to increased neointimal volume. If this process of neointimal growth is exuberant and significantly encroaches on the vascular lumen, it will lead to ISR ([@b70]). As a deeper vascular wall injury stimulates a higher degree of neointimal hyperplasia, the stent deployment injury actually induces more neointimal tissue growth than the BA injury ([@b71]).

Stent-based drug delivery system
================================

The main processes of ISR, smooth muscle cell activation and replication, occur locally at the site of injury. Therefore, one of the most logical approaches is a stent-based drug delivery system to locally deliver an appropriate concentration of an effective agent to stop this process without systemic toxicity. An effective system would consist of 3 components: (1) a metallic platform, (2) a drug carrier vehicle that stores a therapeutic agent as well as allows the agent to diffuse into the vascular tissue in a controlled fashion, and (3) an effective therapeutic agent that reduces the neointimal growth induced by stent implantation. The cross-section of a stent strut with typical coating configuration can be seen in [Figure 2](#fig2){ref-type="fig"}. Therefore, an ideal DES to achieve the greatest clinical efficacy and safety is one that requires an optimization of these three essential parameters.

![Cross-section of a stent strut with a drug-loaded polymeric coating.](vhrm0104-263-f2){#fig2}

Stent design in relation to even drug distribution to vessel wall
-----------------------------------------------------------------

The effect of different stent designs on the drug distribution pattern has been scrutinized in experimental studies and also tested in clinical trials ([@b33]; [@b82]). Recent experimental data suggest that the stent strut configuration directly determines the pattern and degree of drug delivery achieved by DES ([@b33]). The simple proximity of stent struts to vascular tissue does not ensure adequate drug delivery and distribution because most nonuniform distribution has been found in the layers of the artery closest to the stent ([@b33]). After deployment of even highly lipid-soluble and rapidly diffusing agents, homogeneous drug delivery throughout the vessel with uniform concentration at various depths of the vessel wall was not achieved in their study. In the same study, the uniformity of drug distribution was found to be increased with the strut number as well as significantly dependent on the strut pattern of distribution. Therefore, a symmetric expansion of stents with homogeneous distribution of struts is essential for the optimization of drug distribution ([Figure 3](#fig3){ref-type="fig"}). The importance of this concept was further verified by a recent clinical study using Sirolimus-eluting stent (SES) ([@b82]). In the latter study, a nonuniform stent strut distribution and a greater gap distance between struts after stent implantation resulted in more neointimal hyperplasia ([@b82]). Although a large number of stent designs have been developed to date, only the multicellular design is currently most commonly used; they can be categorized into "closed cell" and "open cell" configurations ([@b62]). A closed cell stent has a uniform cell expansion and constant cell spacing when deployed in a curved vascular segment, which gives more uniform drug distribution ([@b62]). An open cell stent has a greater variation in the surface coverage between the inner and outer curvatures in the curved segment, but gives better conformability to curved surface at the expense of less uniform drug distribution ([Figure 3](#fig3){ref-type="fig"}) ([@b62]). The majority of current BMS use a closed cell design. In summary, the optimal stent design for drug delivery should have a large stent surface area, a small cell gap, and minimal strut deformation after deployment while maintaining conformability, radial support, and flexibility to reach the complex coronary lesions.

![Uniform vs nonuniform drug distribution in closed cell vs open cell stents was shown in the longitudinal sections of the vessel wall after a deployment of a drug-eluting stent. Drug concentration was shown in the color intensity in the column. Upper red-brown color is the highest and lower blue color is the lowest drug concentration. (Upper panel). A cross-section of vessel after a deployment of a drug-eluting stent depicts nonuniform strut spacing resulting in uneven drug distribution (Lower panel).](vhrm0104-263-f3){#fig3}

Coating matrix as a reservoir for drugs and controller of kinetic drug release
------------------------------------------------------------------------------

Many methods of coating stents with drugs have been developed for DES ([Figure 4](#fig4){ref-type="fig"}). Some drugs can be bonded directly to a metal stent (eg, prostacyclin, paclitaxel), but most of the agents must be bonded to a matrix polymer, which acts as a drug reservoir to ensure drug retention during deployment and a uniform distribution on the stent ([@b78]). The types, compositions, and designs of the polymers coated on the stent dictate the eluting kinetic of the sustain time release of the drug over a period of weeks or months following the implantation in situ. The coating materials can be categorized as organic vs inorganic, bioerodable vs nonbioerodable, and synthetic vs naturally occurring substances ([@b78]). Generally, for long-term application, a nonbioerodable polymer is used in order to prevent triggering an inflammatory process. The most successfully tested DESs to date have been coated with synthetic polymers; poly-n-butyl methacrylate and polyethylene-vinyl acetate with sirolimus and a poly (lactide-co-Σ-caprolactone) copolymer with paclitax-eleluting stents. All naturally occurring organic materials are both bio- and hemo-compatible ([@b61]; [@b15]). Fibrin, cellulose, and albumin have been tested in animal models, but only phosphorylcholine is used for clinical purposes. Phosphorylcholine is a naturally occurring phospholipid polymer with less potential to elicit inflammation and to interfere with re-endothelialization of the stent surface ([@b40]). BiodivYsio® stents are phosphorylcholine-coated stents currently available ([@b19]). Inorganic substances have also been tested for coating on the stent surface to improve electrochemical properties. One example is a stent coated with a nonporous 300 μm ceramic layer containing tacrolimus-loaded nanocavities ([@b25]).

![Different types of stent-based drug delivery system: (A) Drug released by diffusion from polymer, (B) Drug released by diffusion through ratelimiting coating, (C) Drug released by swelling of coating, (D) Drug release directly from coating, (E) Drug loaded in pore or reservoir in stent, (F) Drug release by erosion of polymer coating, (G) Drug loaded in nanoporous reservoir in coating, (H) Drug loaded between coating layers, (I) Drug released by hydrolysis or enzymatic action from polymer, (J) Bioerodable polymer coating stent.](vhrm0104-263-f4){#fig4}

Therapeutic agents to inhibit neointimal growth
-----------------------------------------------

Many agents with antiinflammatory or antiproliferative properties have been incorporated on the stent surface and tested clinically ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). Many of the agents listed in the tables have more than one mechanism of action. The general mechanism of action for most of these drugs is to stop cell cycle progression by inhibiting DNA synthesis. Everolimus, sirolimus, tacrolimus (FK-506), ABT-578, interferon, dexamethasone, and cyclosporine all fall into this category. In this group, sirolimus and its derivatives were shown to reduce intimal thickening ([@b76]; [@b77]). Dexamethasone-coated BiodivYsio stent also showed a mild to moderate benefit in reducing restenosis ([@b41]). Paclitaxel has been approved for clinical use and ABT-578 also appears promising ([@b48]). Angiopeptin and c-*myc* antisense also has been tested in clinical trials. Migration inhibitors (eg, batimastat) are aimed at preventing smooth muscle cell from migrating into the inside of the stent. If smooth muscle cells migrate to the luminal side of the stent, they can produce extracellular matrix and narrow the vascular lumen ([@b84]). Therefore, inhibition of smooth muscle cell migration may have therapeutic applications for preventing ISR. Examples of these compounds are batimastat and halofuginone ([@b84]). Batimastat inhibits matrix metalloproteinase enzymes and prevents the matrix degradation that is necessary for cells to free themselves to move and invade the stent area ([@b5]). However, a clinical study using batimastat-coated stent failed to show a reduction in restenosis rate when compared with BMS ([@b5]). Enhanced healing factors promote healing of the stent implantation site by reducing platelet aggregation and increasing the rate of re-endothelialization ([@b84]). Estradiols and nitric oxide donor compounds may also replicate this effect ([@b1]; [@b9]). A unique approach of promoting the healing process has been the use of CD34 antibodies-coated stents in order to capture the circulating endothelial progenitor cells ([@b84]). In this experimental model, the surface of the stent was completely re-endothelialized within 48 hours following stent deployment ([@b84]). A first human clinical trial using CD34 antibodies-coated stent has been completed with a result of safety and feasibility in the treatment of de novo coronary artery disease ([@b3]). Therefore, an ideal agent should exert sufficient antirestenotic effects, but also allow re-endothelialization and adequate vessel healing at the site of implantation. It should also have negligible or no systemic effects ([@b45]; [@b78], [@b79]). Only 2 antiproliferative agents, sirolimus and paclitaxel, have been proved to be effective in clinical trials to date ([@b78], [@b79]).

###### 

Agents used in drug-eluting stent

  Antineoplastics and antiinflammatory immunomodulators   Antiproliferative          Migration inhibitors and ECM modulators   Enhanced healing and re-endothelialization factors
  ------------------------------------------------------- -------------------------- ----------------------------------------- ----------------------------------------------------
  Sirolimus                                               QP-2, Taxol(paclitaxel)    Batimastat                                BCP671
  Tacrolimus                                              Actinomycin                Prolyl hydroxylase inhibitors             VEGF
  Everolimus                                              Methotraxate               Halofunginone                             Estradiols
  Leflunomide                                             Angiopeptin                C-proteinase inhibitors                   NO donor compounds
  M-Prednisolone                                          Vincristine                Probucol                                  EPC antibodies
  Dexamethasone                                           Mitomycine                                                           Biorest
  Interferon r-1b                                         Statins                                                              
  Mycophenolic acid                                       C-*myc* antisense                                                    
  Mizoribine                                              Abbott ABT-578                                                       
  Cyclosporine                                            RestenASE                                                            
  Tranilast                                               2-choloro-deoxyadenosine                                             
                                                          PCNA ribozyme                                                        

**Abbreviations:** ECM, extracellular matrix; EPC, endothelial progenitor cells; NO, nitric oxide; PCNA, proliferating cell nuclear antigen; VEGF, vascular endothelial growth factor; QP-2, 7-hexanoyltaxol.

###### 

Clinical trials using agents excluding sirolimus and paclitaxel

  ----------------------------- ----------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tacrolimus                    PRESENT I--III    [Pre]{.ul}liminary [s]{.ul}afety [e]{.ul}valuation of nanoporous [t]{.ul}acrolimus-eluting stents
                                EVIDENT           The [e]{.ul}ndo[v]{.ul}ascular [i]{.ul}nvestigation [d]{.ul}etermining the safety of [n]{.ul}ew [t]{.ul}acrolimus-eluting stent grafts
  Everolimus                    FUTURE I--IV      [F]{.ul}irst [u]{.ul}sed [t]{.ul}o [u]{.ul}nderscore [r]{.ul}eduction in restenosis with [e]{.ul}verolimus
                                SPIRITS-FIRST     
  M-Prednisolone implantation   IMPRESS           [I]{.ul}mmunosuppressive therapy for the [p]{.ul}revention of [res]{.ul}tenosis after coronary artery [s]{.ul}tent
  Dexamethasone                 STRIDE            The [s]{.ul}tudy of an[t]{.ul}i[r]{.ul}estenosis with BiodivYsio [d]{.ul}examethasone-[e]{.ul}luting stent
                                EMPEROR           [E]{.ul}valuation of 9α-F-16 [m]{.ul}ethyl[p]{.ul}rednisolone (dexamethasone)-[e]{.ul}luting stent on the reduction of [r]{.ul}estenosis
                                DESIRE            [D]{.ul}examethasone-[e]{.ul}luting [s]{.ul}tent [I]{.ul}talian [r]{.ul}egistry
                                SAFE              [S]{.ul}orin and [a]{.ul}spirin [f]{.ul}ollowing [e]{.ul}lective [s]{.ul}tenting
  Mycophenolic acid             IMPACT            [I]{.ul}nhibition with [MPA]{.ul} of [c]{.ul}oronary restenosis [t]{.ul}rial
  Batimastat                    BATMAN            BiodivYsio [bat]{.ul}i[m]{.ul}astat SV stent versus balloon [a]{.ul}ngioplasty for the reduction of restenosis in small coronary arteries
                                BRILLIANT         [B]{.ul}atimastat (BB-94) anti[r]{.ul}estenosis trial utilizing the BiodivYsio local drug delivery PC stent
  Actinomycin hyperplasia       ACTION            Recruitment in the [act]{.ul}inomycin-eluting stent [i]{.ul}mproves [o]{.ul}utcomes by reducing [n]{.ul}eointimal
  Angiopeptin                   SWAN              [S]{.ul}tent [wi]{.ul}th angiopepti[n]{.ul}
  C-*myc* antisense             RESTEN-NG         
  Medtronic ABT-578             ENDEAVOR I--III   Randomized controlled trial to evaluate the safety and efficacy of the Medtro[nic]{.ul} AVE ABT-578-eluting [d]{.ul}river™ coronary s[t]{.ul}ent in de novo n[a]{.ul}tive c[or]{.ul}onary a[r]{.ul}tery lesions
  Abbott ABT-578                Zomaxx 1          Zomaxx coronary drug-eluting stent for de novo lesion in coronary arteries.
  Estradiols                    EASTER            [E]{.ul}strogen [a]{.ul}nd [s]{.ul}tent [t]{.ul}o [e]{.ul}liminate [r]{.ul}estenosis
  NO donor compounds            NOBLESSE          [Ni]{.ul}tric [o]{.ul}xide through [bi]{.ul}odegradable [l]{.ul}ayer [e]{.ul}lective [s]{.ul}tudy for [s]{.ul}afety and [e]{.ul}fficacy
  EPC antibodies                HEALING I--II     [H]{.ul}ealthy [e]{.ul}ndothelial [a]{.ul}ccelerated [l]{.ul}ining [i]{.ul}nhibits [n]{.ul}eointimal [g]{.ul}rowth
  ----------------------------- ----------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** MPA, mycophenolic acid; PC, phosphorylcholine; SV, small-vessel.

Sirolimus (rapamycin), a fermentation product of *Streptomyces hygroscopicus*, was discovered in 1977 as an antifungal macrolide antibiotic with potent immunosuppressive properties ([@b59]; [@b46]; [@b80]). Since sirolimus is a lipophilic molecule, it readily diffuses across the cell membranes of vascular smooth muscle cells and leukocytes. Once in the cytoplasm, it binds with high affinity to a specific intracellular protein (FKBP12), and the resultant complex inhibits a regulatory enzyme, called TOR (target of rapamycin). Ultimately it blocks cell cycle progression from G~1~ to S phase, and therefore limits smooth muscle replication and proliferation ([@b59]; [@b46]; [@b80]).

Paclitaxel is an antineoplastic agent originally isolated from the bark of the Pacific yew tree, *Taxus brevifolia* ([@b66]; [@b74]). It was approved by FDA for treatment of breast and ovarian cancer in 1992. It is also a lipophilic molecule that readily diffuses across cell membranes and has a potent stabilizing effect on microtubules ([@b66]; [@b74]). Since microtubule disassembly is essential for the progression of the G2 to M phase in the mitotic cell cycle, stabilization of microtubule inhibits the mitosis of smooth muscle cell as well as inhibits the cell migration. This reduces the infiltration of vascular smooth muscle cells and leukocytes into the zone of injury caused by stent ([@b66]; [@b74]).

Commercially available DES
--------------------------

The sirolimus-eluting Cypher™ stent (Cordis Corp, a Johnson and Johnson Company, Miami, FL, USA) was approved by FDA in April 2003. It is coated with a layer of nonerodable polymer, of 5 μm--10 μm thickness, which is incorporated with sirolimus (140 μg sirolimus/cm^2^ of stent surface area). An additional topcoat is placed on it as a diffusion barrier, which provides the vehicle for controlled release of the drug. It is designed as such that approximately 80% of the total dose of the agent is released in 4 weeks and the remainder over the course of the next 2 weeks ([@b91]). The second commercially available DES is the Taxus™ stent (Boston Scientific, Natrick, MA, USA), which has a proprietary platform, the Express™ stent, and is coated with a proprietary polymer (Translute™) loaded with 1 μg of paclitaxel/mm^2^ of stent surface area. Although there are three drug-release formulations (slow, moderate, and fast), only moderate- and slow-release formulations have been tested in clinical trials ([@b63]; [@b89]). The moderate-release (MR) form of Taxus stent allows for an initial bolus release over the first 48 hours after stenting followed by a low-level release over at least the next 10 days. In the initial 10 days of drug release, the slow-release (SR) formulation of Taxus stent has a drug release concentration of 8--10 times lower than that of the MR formulation. Only SR formulation is used in FDA approved Taxus stents. ([@b63]; [@b89]).

Clinical trials of DES
----------------------

The initial feasibility study of sirolimus-eluting stent (SES), the First In Man (FIM) study, consisted of 45 patients with angina pectoris ([@b76]; [@b77]). There were no major adverse cardiac events (MACE); ie, death, myocardial infarction, coronary bypass grafting, or target lesion revascularization (TLR) at 1- and 2-year clinical follow-up; only minimal neointimal hyperplasia within the stent on angiographic and intravascular ultrasound (IVUS) follow-up at 1 year; and 10% TVR rate for the entire cohort at 2 years ([@b76]; [@b77]). The first randomized clinical trial of SES, the RAVEL ([Ra]{.ul}ndomized study with the sirolimus-eluting Bx [Ve]{.ul}locity balloon-expandable stent) trial, compared the Cypher stent with BMS-Bx Velocity stent in single, noncomplex lesion of native coronary arteries. The RAVEL study result remarkably showed 0% binary restenosis in the SES arm vs 26.6% in the BMS arm at 6-month follow-up, and 5.8% MACE rate in the SES arm vs 28.8% (p \< 0.001) in the BMS arm at 1-year follow-up ([@b52]; [@b72]). The effect of SES in more complex lesions was further confirmed in the larger American trial; SIRIUS ([Sir]{.ul}ol[i]{.ul}m[us]{.ul}-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions). SIRIUS included a greater proportion of patients with high-risk features of restenosis such as diabetes, smaller vessels, and longer lesion requiring overlapping stents. This study showed a restenosis rate of 8.9% in the SES arm vs 36.3% (p \< 0.001) in the BMS arm angiographically at 9-month follow-up ([@b53]). Additional similar SIRIUS trials using SES in Europe and Canada (E- and C-SIRIUS) showed consistent, impressive results. These two studies included a total of 452 patients and had binary restenosis rates 5.9%, 2.3%, respectively, in the SES arm vs 42.3%, 52.3% (p = 0.0001, p \< 0.001) in the BMS arm. The MACE rate was 8.0%, 2.0%, respectively, in the SES arm vs 22.6%, 19.0%, respectively (p = 0.0002, p = 0.0002), in the BMS arm. The TLR rate was 4.0%, 4.0% in the SES arm vs 20.9%, 18%, respectively (p \< 0.0001, p = 0.05), in the control arm at 9-month follow-up ([@b67]; [@b65]). Results of these clinical trials are summarized in [Table 3](#tbl3){ref-type="table"}.

###### 

Summary of randomized controlled trials of sirolimus-eluting stent vs bare metal stent

                                  RAVEL   SIRIUS   E-SIRIUS   C-SIRIUS                        
  ------------------------------- ------- -------- ---------- ---------- ------ ------ ------ ------
  Mean lesion length (mm)         9.56    9.61     14.4       14.4       14.9   15.1   14.5   12.6
  Mean RVD (mm)                   2.6     2.64     2.79       2.81       2.6    2.51   2.65   2.62
  Angiographic follow-up          6 mon   9 mon    9 mon      9 mon                           
  Mean late luminal loss\* (mm)   −0.01   0.80     0.24       0.81       0.19   0.80   0.12   0.79
  Binary restenosis(%)            0       26.6     8.9        36.3       5.9    42.3   2.3    52.3
  Subacute stent thrombosis (%)   0       0        0.4        0.8        1.1    0      2.0    2.0
  TVR (%)                         0       26       3.4        4.8        4.0    20.9   --     --
  TLR (%)                         0       23.7     4.1        16.6       4.0    20.9   4.0    18.0
  Overall MACE (%)                5.8     28.8     7.1        18.9       8.0    22.6   4.0    18.3

**Abbreviations:** RAVEL, [Ra]{.ul}ndomized study with sirolimus-eluting [Ve]{.ul}locity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesion; SIRIUS, [Sir]{.ul}olim[us]{.ul}-coated BX Velocity stent in the treatment of patients with de novo coronary artery lesions; E- & C-SIRIUS, European- & Canadian-SIRIUS; MACE, major adverse cardiac events; mon, months; RVD, reference vessel diameter; TLR, target lesion revascularization; TVR, target vessel revascularization.

[note]{.smallcaps}: All mean late luminal loss were in-segment except for RAVEL which was in-stent.

Unlike SES, paclitaxel and its derivatives have been studied in different coatings and stent designs. There were mainly 3 types of paclitaxel coatings: (1) 7-hexanoyltaxol which used polyacrylate sleeves as a release mechanism tested in the SCORE ([S]{.ul}tudy to [co]{.ul}mpare [re]{.ul}stenosis rate between QueSt and QuaDS-QP2) trial; (2) Paclitaxel-eluting stent (PES), which used nonpolymer coating as platform tested in 3 other trials; ELUTES ([E]{.ul}uropean eva[lu]{.ul}ation of pacli[t]{.ul}axel-[e]{.ul}luting stent), ASPECT ([As]{.ul}ian [p]{.ul}aclitaxel-[e]{.ul}luting stent [c]{.ul}linical [t]{.ul}rial), and DELIVER (Paclitaxel-coated RX ACHIEVE coronary stent system \[CSS\] versus the RX ML PENTA stainless steel stent in the treatment of focal de novo coronary lesions); and (3) PES which used polymer coating as a platform tested in TAXUS I--VI trials ([@b24]; [@b29]; [@b20]; [@b36]). Except for the polymer-coated-PES, the other two types of coating have not been very suitable or useful ([@b24]; [@b29]; [@b20]; [@b36]). The initial feasibility study of polymer-based PES, TAXUS I, was performed in Europe where the feasibility of using a SR-PES to treat short (\<15 mm) de novo lesions was demonstrated ([@b25]). TAXUS II was the first randomized trial using both SR- and MR-PESs with a binary restenosis rate of 5.5% in SR and 8.6% in MR, respectively, vs 21.9% in BMS arm ([@b7]). TAXUS III was a feasibility trial of SR-PES in ISR with the result of feasible and safe use in the treatment of ISR in 28 patients with a MACE rate of 29% ([@b85]). TAXUS IV, a major pivotal American trial of PES compared with BMS, showed significant reduction in the TLR rate (4.4% vs 15.1%, p \< 0.0001), TVR rate (7.1% vs 17.1%, p \< 0.0001), and composite MACE rate (10.8% vs 20.0%, p \< 0.0001) ([@b81]). TAXUS VI was a randomized trial using MR-PES in complex lesions such as very long lesions or lesions in small vessels. The results showed in-stent binary restenosis rate of 12.4% vs 35.7% (p \< 0.0001), TLR rate of 6.8% vs 18.9% (p = 0.0001) and TVR rate of 9.1% vs 19.4% (p = 0.0027) when comparing PES with BMS arm at 9 months ([@b12]; [@b23]). The results of published randomized controlled trials using PES are summarized in [Table 4](#tbl4){ref-type="table"}.

###### 

Summary of randomized controlled trials of paclitaxel-eluting stent vs bare metal stent

                                   TAXUS I    TAXUS II   TAXUS IV   TAXUS VI                                       
  -------------------------------- ---------- ---------- ---------- ---------- ------ ------ ------ -------------- ------------
  Lesion length (mm)               11.9       10.7       10.6       10.6       10.2   13.4   13.4   20.32          20.94
  RVD (mm)                         2.94       2.99       2.78       2.8        2.7    2.75   2.75   2.77           2.81
  Late luminal loss (mm)           0.71       0.36       0.78       0.31       0.3    0.61   0.23   0.99           0.39
  In-stent binary restenosis (%)   10         0          21.9       5.5        8.6    26.6   7.9    32.9           9.1
  Stent thrombosis (%)             0          0          0          1.5        0.7    0.8    0.6    0              0
  TLR or TVR (%)                   10 or 10   0 or 3.3   17.5       10.1       6.9    12.0   4.7    18.9 or 19.4   6.8 or 9.1
  Overall MACE (%)                 10         3.3        21.7       10.9       9.9    15.0   8.5    22.5           16.4

**Abbreviations:** MACE, major adverse cardiovascular events; MR, moderate-release; RVD, reference vessel diameter; SR, slow-release; TLR, target lesion revascularization; TVR, target vessel revascularization.

Other promising DES in clinical trials
--------------------------------------

Stents coated with rapamycin analogues, ABT-578, and everolimus were also studied in clinical trials. In the ENDEAVOR I (Randomized controlled trial to [e]{.ul}valuate the safety and efficacy of the Medtronic AVE ABT-578-eluting [d]{.ul}river™ coronary st[e]{.ul}nt in de novo n[a]{.ul}ti[v]{.ul}e c[o]{.ul}ronary a[r]{.ul}tery lesions) trial, ABT-578 (Abbott Laboratories, Abbott Park, IL, USA) coated cobalt-alloy stent (Driver stent, Medtronic Inc, Minneapolis, MN, USA) was used to treat 100 patients with de novo lesions. The result showed 0.33 mm of angiographic in-stent late lumen loss at 4 months and 0.58 mm at one-year follow-up. The target-vessel failure rate was comparable to the results of SIRIUS or TAXUS IV ([@b48]). ENDEAVOR II and III are large pivotal trials for ABT-578 and the results are pending. FUTURE ([F]{.ul}irst [u]{.ul}sed [t]{.ul}o [u]{.ul}nderscore [r]{.ul}eduction in restenosis with [e]{.ul}verolimus) I and II trials were designed to demonstrate the safety and feasibility of the everolimus-eluting-stent (Novartis Pharma AG, Basel, Switzerland) in a small population with focal de novo coronary artery lesions with a in-stent late lumen loss of 0.12 mm, a low TLR rate (4.3%) and a very low MACE rate (6.4%) at 6-month follow-up ([@b10]). A large clinical trial for everolimuseluting stent is ongoing.

Real world experience of DES
----------------------------

The "real world" registries are important because patients in clinical trials of DES are highly selected groups of patients and these clinical trials do not include patients with high-risk lesions for restenosis such as small-vessel, very long lesions, ostial lesions, left main lesions, bifurcation lesions, totally occluded and saphenous vein lesions, and lesions in acute myocardial infarction. However, these registries gather the clinical outcomes of DES use in unselected population to further validate its clinical efficacy. SES currently has 2 major registries, RESEARCH and E-Cypher. PES has 3 major registries, WISDOM, MILESTONE II, and ARRIVE. The RESEARCH ([R]{.ul}apamycin-[e]{.ul}luting [s]{.ul}tent [e]{.ul}valuated [a]{.ul}t [R]{.ul}otterdam [C]{.ul}ardiology [H]{.ul}ospital) registry is a single-center registry of an unrestricted use of SES in all patients with de novo lesions to evaluate the safety and efficacy in the daily practice at 1-year period compared with a control group who received BMS in the previous year. This registry had excellent results with lower TLR rate (5.1% vs 10.9%) and MACE rate (9.7% vs 14.8%) ([@b39]).

E-Cypher is an international internet-based registry of SES that enrolled all patients receiving one and more SES with current recruitment of more than 12 000 patients in 275 international sites and more than 80% eligible patients at 6-month follow-up. This registry showed absolutely stunning outcomes of 2.95% MACE rate, 1% TLR rate, and 0.3% SAT rate at 6 months ([@b86]). WISDOM (Web-based Taxus intercontinental observational data transitional registry program) was a multicenter registry of 778 patients who received PES without strict clinical and angiographic inclusion criteria. The interim result of this registry showed a TLR rate of 1.8% and a MACE rate of 4.5% ([@b2]). MILESTONE II was a European and intercontinental post-market registry of 3708 patients who received PES compared with the result of MILESTONE I which used BMS. MILESTONE II included the high-risk lesions and diabetic patients, especially insulin dependent diabetes, and it also had successful results of 7.1% MACE rate, 4.2% of TVR rate and 0.9% of stent thrombosis rate (acute and late angiographic restenosis) at 6 months with the diabetic population having 8.9% MACE rate and 5% TVR rate ([@b4]). ARRIVE is a peri-approval Taxus stent registry of 2600 consecutive patients at 50 centers in USA and showed the result of 2.7% MACE rate and 1.3% of stent thrombosis rate at 30 days ([@b11]). The clinical outcomes of these registries showed that the use of DES in the real world practice, ie, in a larger and unselected patient population, achieved similarly successful outcome as those of previous randomized trials.

Current issues of DES
=====================

Expanded indications
--------------------

Although DES was proved to be a safe and effective method in the treatment of coronary artery stenosis by both randomized clinical trials and real world practice, its expanded indications in complex and high-risk lesions for restenosis such as totally occluded lesions, left main lesions, bifurcation lesions, ostial lesions, small and long lesions, saphenous vein graft lesion, ISR, and diabetes mellitus are still under evaluation with ongoing trials. The results of clinical trials for some expanded indications are now available.

Of the high-risk subsets, diabetes mellitus is the most common and important one. Subanalysis of diabetic patients in the many clinical trials such as SIRIUS, TAXUS IV, or E-Cypher registry showed a great efficacy of DES in these patients even though these trials were not designed to investigate the efficacy in diabetes mellitus. SIRIUS study showed excellent results with a MACE rate of 9.2% vs 25% (p \< 0.001) and a TLR rate of 6.9% vs 22.3% (p \< 0.001) in the SES arm compared with the BMS arm at 9-month follow-up ([@b55]). In the diabetic group of the E-Cypher registry, the results were 4.2% MACE, 1.4% TLR, and 0.5% SAT with similar result in insulin dependent diabetic subset; 5.9% MACE, 1.5% TLR, and 0.4% SAT (p \< 0.01) ([@b21]). In the TAXUS IV trial, similar results were shown in diabetic patients with a binary angiographic restenosis rate of 6.4% in PES arm vs 34.5% in BMS arm (p \< 0.0001) at 9-month follow-up, the TLR rate of 7.4% vs 20.9% (p = 0.0008) and TVR rate of 11.3% vs 24% (p \< 0.004), respectively, at 12-month follow-up. More specifically, in insulin dependent diabetic subset, a very similar rate of angiographic restenosis 7.7% vs 42.9% (p = 0.0065), and TLR rate of 6.2% vs 19.4% (p = 0.07), when compared with BMS was found to exist ([@b27]). A large comparison study using DES in treating multi-vessel disease in diabetic patients with coronary bypass surgery is currently ongoing.

In the subset of the lesions in small vessels, the data from the RESEARCH registry showed that the larger vessels group (reference vessel diameter of 2.52 mm ± 0.57 mm) has a late loss of 0.03 mm ± 0.38 mm and binary restenosis rate of 3.9% whereas the small vessels group (reference vessel diameter of 1.88 mm ± 0.34 mm) has a late loss of 0.07 mm ± 0.48 mm and a restenosis rate of 10.7%. ([@b37]). In the SIRIUS trial, the small vessel (reverence vessel diameter \[RVD\] ≤2.3 mm) subset study showed an in-lesion restenosis rate of 18.6% in the SES group vs 42.9% in the control group (p \< 0.001) ([@b26]). Moreover, with an improved deployment technique to cover the full length of lesions, a different trial, ie, [S]{.ul}mall [v]{.ul}ess[el]{.ul}s treated with the Cypher s[te]{.ul}nt (SVELTE) was performed. The SVELTE trial was a prospective study using Cypher stent in small-vessel lesions (RVD of 2.25 mm--2.75 mm) while comparing the historical control from the SIRIUS trial. The findings indicated a better in-stent binary restenosis rate of 3.2% in SVELTE group vs 3.9% in SIRIUS-SES group and 38.0% in SIRIUS-control group with much improved in-lesion restenosis rate of 6.3% vs 11.6% and 39.0%, respectively ([@b75]).

For very long lesions, the study from the RESEARCH registry examining patients with long lesions with a SES stent length of 39 mm ± 29 mm (mean ± standard deviation) showed an in-stent late loss 0.13 mm ± 0.47 mm at 6-month follow-up and a TVR rate of 6.2% and a MACE rate of 8.3% at 320-day follow-up ([@b14]). The TAXUS VI study for very long lesions (18 mm--40 mm in lesion length) showed a very impressive low TLR rate of 6.8% in the PES arm vs 18.9% in the BMS arm at 9 month follow-up ([@b13]).

In a totally occluded lesion substudy, the data from RESEARCH registry showed a reduction in the MACE rate (cumulative MACE-free survival rate of 96.4% in SES arm vs 82.1% in BMS arm) and a binary restenosis rate of 9.1% in the SES arm vs other BMS trials for total occluded lesions: 55% in TOSCA ([T]{.ul}otal [o]{.ul}cclusion [s]{.ul}tudy of [C]{.ul}anada); 42% in STOP ([S]{.ul}tents in [t]{.ul}otal [o]{.ul}cclusion for restenosis [p]{.ul}revention); 32% in GISSOC ([G]{.ul}ruppo [i]{.ul}taliano di [s]{.ul}tudio sullo [s]{.ul}tent nelle [o]{.ul}cclusioni [c]{.ul}oronariche) and 32% in SICCO (Stenting in [C]{.ul}hronic [C]{.ul}oronary [O]{.ul}cclusion) ([@b30]). In addition, SICTO ([S]{.ul}irolimus-eluting stent [i]{.ul}n [c]{.ul}hronic [t]{.ul}otal [o]{.ul}cclusion) was a multicenter, prospective and nonrandomized feasibility study of SES in treatment of patients with chronic total occlusion and showed a persistently pristine result of late loss (−0.1 mm ± 0.3 mm) and a TVR rate of 8% at 6-month follow-up ([@b44]).

For the treatment of in-stent restenosis, TAXUS III trial, a feasibility and safety study, showed a result of 21% TLR rate and a binary restenosis rate of 16% in the PES arm ([@b85]). In RESEARCH registry, the SES group had the results of a MACE rate of 18.6% and a TVR rate of 4.7% similar to the results of the brachytherapy group, 20.9%, 4.7%, respectively, at 9-month follow-up ([@b64]). But much more strikingly, TROPICAL (Sirolimus-eluting stent in the [tr]{.ul}eatment [o]{.ul}f [p]{.ul}atients with [i]{.ul}n-stent restenotic native [c]{.ul}oronary [a]{.ul}rtery [l]{.ul}esion) was a multicenter, nonrandomized study that showed a much better result of stent thrombosis rate (0.6% vs 3.9%), binary restenosis rate (9.7% vs 40.3%), and MACE rate (3.7% vs 18.8%) in the SES arm when compared with the historic control from the brachytherapy trials (GAMMA I and II) ([@b58]). The ISAR-DESIRE (Intracoronary stenting and [a]{.ul}ngiographic [r]{.ul}esults: [d]{.ul}rug-[e]{.ul}luting [s]{.ul}tent for [i]{.ul}n-[s]{.ul}tent [r]{.ul}estenosis) trial was a 3-arm study comparing the efficacy of SES, PES, and BA in patients with ISR. Both SES and PES were associated with a lower TVR rate and smaller late lumen loss than use of BA at 9 months ([@b35]).

In patients with bifurcation lesions, RESEARCH registry showed encouraging TLR rate (8.6%) and binary restenosis rate (22.7%) in SES group ([@b64]). [@b8] described a safety and efficacy of SES in the treatment of bifurcation lesion with the result of TLR rate of 17.6% and binary restenosis rate of 25.7% but it was concluded that restenosis at the side branch remained a problem ([@b8]). The use of DES in left main lesion and the vein graft lesion is still under clinical investigation.

In terms of the superiority of DES, two large randomized clinical trials in head-to-head comparison of the efficacy of SES to PES in patients with de novo lesions, ie, REALITY (A prospective, randomized, multi-[c]{.ul}enter comp[a]{.ul}rison of the cypher sirolimus-eluting and the Taxus paclitaxel-eluting stent s[y]{.ul}stems) and SIRTAX (Randomized comparison of a [sir]{.ul}olimus- vs a paclitaxel-eluting ([Tax]{.ul}us) stent for coronary revascularization) were recently completed. The result of REALTY trial showed no difference between SES and PES in binary angiographic in-lesion restenosis at 8 months (9.6% Cypher vs 11.1% TAXUS), but all angiographic parameters favored more robust inhibition of neointimal hyerplasia by Cypher (in-stent late loss: 0.09 mm vs 0.31 mm; diameter stenosis%: 23.1% vs 26.7%; in-stent minimal luminal diameter: 2.0 mm vs 1.85 mm) ([@b51]). In the SIRTAX trial, SES showed a lower in-stent and in-lesion late luminal loss than PES (0.13 mm vs 0.25 mm, 0.19 mm vs 0.32 mm respectively) as well as a lower in-stent and in-lesion binary restenosis than PES (3.2% vs 7.6%, 6.7% vs 11.9%, respectively) ([@b90]).

SAT and late stent thrombosis
-----------------------------

Subacute stent thrombosis is approximately 1% in patients on dual antiplatelet therapy. However, an IVUS study has revealed that inadequate stent expansion was related to SAT. An adequate stent expansion and IVUS guided stent implantation had been shown to reduce the SAT rate ([@b54]). However, there was a case report of an occurrence of late stent thrombosis in one patient who discontinued clopidogrel at 18 month after SES implantation ([@b88]). Subsequetly, a 2nd case report revealed four patients developed similar late stent thrombosis following the discontinuation of clopidogrel after 1 year of PES implantation. ([@b47]). This has raised the question of whether there is a need to increase the duration of antiplatelet therapy for patients receiving DES beyond the current recommended guidelines of practice.

Issue of stent-based delivery: incomplete stent apposition and uneven stent strut distribution
----------------------------------------------------------------------------------------------

Incomplete stent apposition (ISA), defined as one or more stent struts not in contact with vascular wall on IVUS at any point in time after stent implantation, was found in 21% of the SES arm in RAVEL vs 4% in the BMS arm at 6-month follow-up ([@b72]). It is possible that this is due to either an initial incomplete deployment of stent during implantation or positive remodeling of vessel wall but other mechanisms like plaque regression, cell necrosis, apoptosis, and allergic reaction to sirolimus have been postulated ([@b38]; [@b82]). Uneven stent strut distribution and incomplete wall apposition has been considered to be the causes of ISR after the DES implantation in two clinical studies ([@b38]; [@b82]).

Economic burden
---------------

One of the thorniest issues regarding DES is their cost and reimbursement. In the USA, a BMS costs approximately \$900--\$1200 each while a DES costs approximately \$3065--\$3195. However, in the cost-effective analysis of SIRIUS trial, the difference of cost between the 2 groups were only about US \$300 at 1 year, despite an initial \$3000 difference after hospitalization ([@b6]). The advent of more varieties of DES in near future will minimize the cost issue and make DES available to all patients.

Conclusion
==========

The recent introduction of DES in PCI is a major innovative advancement in interventional cardiology. DES dramatically reduces the ISR rate in all subgroups of patients in both randomized clinical trials and real-world practice. Continuing improvement in drug-delivery stent technologies and gradual reduction in cost would make DES an effective mainstay of therapy for coronary artery disease.
